公开(公告)号：US20240325497A1

公开(公告)日：2024-10-03

申请号：US18580971

申请日：2022-08-03

Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY

Inventor： Cheol Ryong KU ,  Ju Hun OH ,  Chan Woo KANG ,  Eun Kyung WANG ,  Zhenyu HONG ,  Yong Ho LEE

IPC: A61K38/22 ,  A61K9/00 ,  A61P1/16

CPC classification number: A61K38/22 ,  A61K9/0056 ,  A61P1/16

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating liver disease comprising STC-1 or a derivative thereof as an active ingredient. The STC-1 protein according to the present invention reduces the expression of liver fibrosis markers ALT and Lect2 and reduces the area of fibrotic tissue, in animal models of liver fibrosis, indicating that it has excellent effects on the prevention and treatment of liver fibrosis and, furthermore, cirrhosis.

公开(公告)号：US20240058291A1

公开(公告)日：2024-02-22

申请号：US18260824

申请日：2022-02-10

Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY ,  ARONTIER CO., LTD.

Inventor： Cheol Ryong KU ,  Chan Woo KANG ,  Eun Kyung WANG ,  Ju Hun OH ,  Zhenyu HONG ,  Insuk SOHN ,  Un Ho KANG

IPC: A61K31/215 ,  A61P3/10

CPC classification number: A61K31/215 ,  A61P3/10

Abstract: The present invention relates to a composition for regulating glucose that regulates the amount of glucose metabolized in the small intestine. According to the present invention, it is possible to improve glucose metabolism in the small intestine and to promote blood glucose excretion into feces, thus lowering blood glucose concentration, thereby preventing, alleviating or treating metabolic disease.